Most Important GLP-1 Studies 2023–2026: The Evidence Behind Ozempic, Wegovy, Mounjaro, Zepbound and the Next Generation

- September 22, 2026

By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: September 2026

GLP-1 medicines have moved from being primarily diabetes treatments to becoming a major platform for obesity and cardiometabolic medicine. The strongest clinical-trial evidence now extends beyond weight loss to cardiovascular disease, chronic kidney disease, heart failure, metabolic liver disease and other obesity-related complications. But "GLP-1" is not one drug, and the studies are not interchangeable. Semaglutide, tirzepatide, liraglutide and newer investigational medicines act on overlapping but different metabolic pathways, and the populations, doses and outcomes studied vary substantially.

Key takeaway: The most important GLP-1 evidence through 2026 falls into several categories: weight loss, cardiovascular outcomes, kidney outcomes, heart failure, metabolic liver disease, diabetes control, long-term weight maintenance and next-generation multi-receptor drugs. The strongest conclusions come from randomized controlled trials with clinically meaningful endpoints, not from small mechanistic studies or testimonials.

What are GLP-1 drugs?
The GLP-1 evidence map
SELECT: semaglutide and cardiovascular disease
STEP trials: semaglutide and weight loss
SURMOUNT trials: tirzepatide and obesity
SURMOUNT-5: tirzepatide vs semaglutide
FLOW: semaglutide and chronic kidney disease
SUMMIT: tirzepatide, obesity and heart failure
Semaglutide and metabolic liver disease
The oral GLP-1 era: Wegovy tablets and orforglipron
Retatrutide and triple-agonist research
What the studies say about safety
What we know vs what remains uncertain
Evidence grading
Clinical takeaways
Key studies and sources
Frequently asked questions

What Are GLP-1 Drugs?

GLP-1, or glucagon-like peptide-1, is an incretin hormone involved in glucose regulation, appetite and gastrointestinal function. GLP-1 receptor agonists mimic some of the hormone's physiological effects.

These medicines can increase glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying to varying degrees and influence appetite-regulating pathways in the brain. The result can be lower food intake, improved glycemic control and substantial weight loss.

Not all modern obesity medicines are pure GLP-1 receptor agonists. Tirzepatide activates both the GIP and GLP-1 receptors, while retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

Medicine / class	Main pathway	Current status in the U.S.	Major role
Semaglutide	GLP-1 receptor agonist	Approved	Type 2 diabetes, obesity/overweight and selected cardiovascular risk indications
Tirzepatide	GIP + GLP-1 receptor agonist	Approved	Type 2 diabetes, obesity/overweight and selected obesity-related conditions
Liraglutide	GLP-1 receptor agonist	Approved	Diabetes and obesity
Orforglipron	Oral small-molecule GLP-1 receptor agonist	Approved in 2026	Obesity/overweight
Retatrutide	GIP + GLP-1 + glucagon receptor agonist	Investigational	Obesity and metabolic disease research
Zenagamtide (amycretin)	GLP-1 + amylin receptor agonism	Investigational	Obesity and diabetes research

Regulatory status can change as applications and approvals evolve. Investigational medicines should not be treated as equivalent to FDA-approved therapies.

The GLP-1 Evidence Map: Which Studies Matter Most?

The table below is a practical map of the landmark trials that changed how clinicians think about this drug class.

Trial	Drug	Primary question	Why it matters	Evidence level
STEP-1	Semaglutide	Weight loss	Established approximately 15% mean weight loss over 68 weeks in adults with overweight/obesity without diabetes	E5
SELECT	Semaglutide	Cardiovascular outcomes	Reduced major cardiovascular events in people with overweight/obesity and established cardiovascular disease without diabetes	E5
SURMOUNT-1	Tirzepatide	Weight loss	Demonstrated very large and sustained weight reductions	E5
SURMOUNT-5	Tirzepatide vs semaglutide	Head-to-head obesity treatment	Tirzepatide produced greater mean weight loss	E5
FLOW	Semaglutide	Kidney outcomes	Reduced major kidney events in type 2 diabetes with chronic kidney disease	E5
SUMMIT	Tirzepatide	Heart failure with preserved EF	Improved heart-failure outcomes and symptoms in obesity-related HFpEF	E5
ESSENCE	Semaglutide	MASH	Demonstrated histologic benefit in metabolic dysfunction-associated steatohepatitis with fibrosis in phase 3 research	E5
OASIS 4	Oral semaglutide	Weight loss	Showed substantial weight loss from daily oral semaglutide	E5
ATTAIN-1	Orforglipron	Oral obesity treatment	Confirmed clinically meaningful weight loss with an oral small-molecule GLP-1 agonist	E5
TRIUMPH	Retatrutide	Next-generation obesity treatment	Very large phase 3 weight-loss results, but the medicine remains investigational	E4–E5*

*Retatrutide phase 3 evidence is increasingly strong, but results remain part of an investigational development program until full regulatory review and authorization. Some 2026 results were initially reported by the manufacturer as topline data.

1. SELECT: Semaglutide and Cardiovascular Disease

Why SELECT changed the GLP-1 story

The SELECT trial was one of the most important obesity trials ever conducted because it asked a question that went beyond the scale: Can semaglutide reduce major cardiovascular events in people with overweight or obesity who do not have diabetes but already have cardiovascular disease?

The trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes. Participants received once-weekly semaglutide 2.4 mg or placebo.

The primary composite endpoint of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% of participants receiving semaglutide versus 8.0% receiving placebo, corresponding to a hazard ratio of 0.80.

What SELECT actually proved: In the studied population, semaglutide reduced the risk of major cardiovascular events compared with placebo. This is stronger evidence than simply showing improvements in blood pressure, cholesterol or body weight.

The FDA subsequently expanded Wegovy's U.S. indication to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

Source: NEJM — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
FDA — Wegovy cardiovascular-risk indication

2. STEP Trials: Semaglutide and Weight Loss

The STEP program established semaglutide 2.4 mg as one of the most effective pharmacologic approaches to weight management available at the time of its development.

STEP-1

In STEP-1, 1,961 adults with overweight or obesity but without diabetes received semaglutide 2.4 mg weekly or placebo alongside lifestyle intervention for 68 weeks.

Mean weight change was approximately −14.9% with semaglutide versus −2.4% with placebo.

This trial helped establish a new benchmark for anti-obesity medication efficacy.

Source: NEJM — STEP-1

Why the STEP program matters

STEP studies also helped answer questions about maintenance, diabetes status, dose and the importance of combining pharmacotherapy with lifestyle intervention.

One lesson has become increasingly clear: obesity pharmacotherapy is generally a long-term treatment strategy rather than a short cosmetic intervention. When treatment is stopped, substantial weight regain can occur in many patients.

3. SURMOUNT: Tirzepatide and Obesity

Tirzepatide is pharmacologically distinct from semaglutide because it activates both the GIP and GLP-1 receptors.

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and at least one weight-related complication, without diabetes. Participants received tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks.

The trial demonstrated substantial mean weight reductions across the tirzepatide dose groups, with the largest reductions occurring at the highest studied dose.

Gastrointestinal effects were the most common adverse events and generally occurred during dose escalation.

Source: NEJM — SURMOUNT-1

4. SURMOUNT-5: Tirzepatide vs Semaglutide

One of the most clinically useful GLP-1 studies was the direct comparison of tirzepatide and semaglutide.

In SURMOUNT-5, adults with obesity but without type 2 diabetes were randomized to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks.

Mean weight reduction was approximately:

Treatment	Mean weight change at 72 weeks
Tirzepatide	−20.2%
Semaglutide	−13.7%

Tirzepatide was therefore superior to semaglutide for mean weight reduction and waist-circumference reduction in this particular study population.

Important: This does not mean tirzepatide is automatically "better" for every patient. The trial tested a specific population, dosing strategy and outcome. Treatment choice also depends on diabetes status, cardiovascular disease, kidney disease, heart failure, adverse effects, contraindications, cost, access and individual response.

Source: NEJM — SURMOUNT-5

5. FLOW: Semaglutide and Chronic Kidney Disease

The FLOW trial extended the evidence base for semaglutide from glucose and weight management into kidney outcomes.

FLOW studied people with type 2 diabetes and chronic kidney disease. Semaglutide reduced the risk of major kidney and cardiovascular outcomes compared with placebo.

This is important because kidney protection is a clinical endpoint, not simply a surrogate improvement in laboratory values.

The trial reinforces the broader evolution of GLP-1 therapy toward organ-protection and cardiometabolic risk management.

Source: NEJM — FLOW

6. SUMMIT: Tirzepatide, Obesity and Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction, or HFpEF, is strongly associated with obesity and metabolic dysfunction.

The SUMMIT trial evaluated tirzepatide in people with obesity and HFpEF. The trial found a lower risk of the composite of cardiovascular death or worsening heart-failure events, with the difference driven mainly by fewer worsening heart-failure events.

Tirzepatide also improved symptoms, physical limitations and body weight.

Why this matters: The significance of SUMMIT is not simply that patients lost weight. It suggests that treatment of obesity with tirzepatide may improve clinically important outcomes in an obesity-related heart-failure population.

7. Semaglutide and Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis, or MASH, is one of the most important emerging areas for incretin-based therapies.

In the phase 3 ESSENCE trial, semaglutide 2.4 mg was studied in adults with biopsy-defined MASH and stage 2 or 3 fibrosis.

The study provided evidence of histologic improvement in MASH and increased the scientific interest in GLP-1 and related metabolic therapies for fatty-liver disease.

However, liver disease claims need careful interpretation. A drug that causes weight loss is not automatically a treatment for every stage of fibrosis or cirrhosis, and individual indications depend on the specific medicine, regulatory label and disease stage.

Source: NEJM — Phase 3 Trial of Semaglutide in MASH

8. The Oral GLP-1 Era: Wegovy Pill vs Foundayo Pill

One of the biggest changes in 2026 is that the GLP-1 field is no longer defined only by injections.

Oral semaglutide

The OASIS program demonstrated that oral semaglutide can produce clinically meaningful weight loss. OASIS 4 studied a 25 mg once-daily dose in adults with overweight or obesity without diabetes.

This expanded the evidence base for oral semaglutide as an alternative route of administration.

FDA documentation confirms that Wegovy tablets are now part of the U.S. semaglutide product family, alongside injectable formulations.

Source: NEJM — OASIS 4
FDA — Wegovy tablets approval letter

Orforglipron

Orforglipron is an oral, nonpeptide small-molecule GLP-1 receptor agonist.

In the phase 3 ATTAIN-1 trial, adults with obesity without diabetes experienced significantly greater weight reduction with orforglipron than with placebo at 72 weeks.

The highest studied dose produced an average weight reduction of approximately 11.2% compared with approximately 2.1% with placebo in the primary analysis.

The FDA approved Foundayo (orforglipron) on April 1, 2026 for adults with obesity or overweight with a weight-related comorbidity, in combination with reduced-calorie diet and increased physical activity.

Source: NEJM — ATTAIN-1
FDA — Foundayo approval

9. Retatrutide: The Next Generation of GLP-1 Research

Retatrutide represents a different strategy from conventional GLP-1 receptor agonists.

It is an investigational triple agonist targeting:

GIP GLP-1 Glucagon

The rationale is that combining these pathways may produce greater effects on appetite, energy balance, glucose metabolism and body weight.

Phase 3 results are changing expectations

In 2026, phase 3 results from the TRIUMPH program reported exceptionally large weight reductions. In TRIUMPH-1, the company reported approximately 28.3% average weight loss at 80 weeks with 12 mg retatrutide in adults with obesity without diabetes.

TRIUMPH-4 also reported very large weight reductions in people with obesity and knee osteoarthritis.

Retatrutide is not the same as tirzepatide or semaglutide. It remains an investigational medicine. It should not be presented as an FDA-approved treatment, and unapproved retatrutide products marketed outside legitimate clinical research or regulatory channels raise additional quality and safety concerns.

The FDA has specifically stated that retatrutide is not an active ingredient in an FDA-approved drug and has warned about unapproved retatrutide being marketed directly to consumers or offered for compounding.

Sources: Eli Lilly — TRIUMPH-1 results
Eli Lilly — TRIUMPH-4 results
FDA — Concerns with unapproved GLP-1 drugs

10. Wegovy HD and Higher-Dose Semaglutide

Another major 2026 development is the higher-dose semaglutide formulation known as Wegovy HD.

In March 2026, the FDA approved the 7.2 mg Wegovy formulation for weight loss and long-term maintenance of weight reduction in eligible adults with obesity or overweight plus a weight-related condition.

This illustrates a broader trend in obesity medicine: developers are not only creating new molecules but also testing whether higher doses or different formulations can extend efficacy.

Source: FDA — Wegovy HD approval

11. What the GLP-1 Studies Say About Safety

The large randomized trials provide a much more useful safety picture than isolated anecdotes.

Common adverse effects

The most common adverse effects across semaglutide and tirzepatide obesity studies are gastrointestinal:

Issue	What the evidence suggests
Nausea	Common, particularly during dose escalation
Vomiting	Can occur, generally concentrated around dose escalation
Diarrhea	Common with several incretin therapies
Constipation	Common, especially with weight-loss doses
Abdominal discomfort	Reported in clinical trials
Gallbladder disease	Recognized potential adverse effect and monitored in labeling
Pancreatitis	Important safety consideration requiring clinical attention when suspected
Dehydration / acute kidney injury	Can occur indirectly, particularly when severe gastrointestinal symptoms cause volume depletion

Thyroid C-cell tumor warning

Semaglutide products carry a boxed warning concerning thyroid C-cell tumors based on findings in rodents. The human relevance of these findings is unknown, and the medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

This warning should not be confused with proof that semaglutide causes thyroid cancer in humans.

Source: DailyMed — Wegovy current labeling

Suicidal thoughts and GLP-1 medicines

This topic needs a 2026 update. In January 2026, the FDA stated that its comprehensive evaluation did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of the warning from affected product labeling.

That is an important correction to older articles that continue to describe suicidal behavior as an established GLP-1 drug risk.

Source: FDA — January 2026 GLP-1 safety update

12. Bone, Muscle and "Lean Mass" Questions

The rapid weight-loss effects of GLP-1 medicines have created legitimate scientific questions about body composition.

When people lose a large amount of body weight, they generally lose both fat mass and some lean mass. That does not automatically mean that the medication is "damaging muscle," because changes in lean mass must be interpreted relative to total weight loss and changes in fat mass.

For patients using potent anti-obesity medicines, preserving physical function may therefore require an active strategy involving adequate protein intake, resistance exercise and appropriate nutritional monitoring.

Long-term skeletal outcomes remain an area of active research. Claims that GLP-1 drugs broadly cause osteoporosis or tendon rupture should not be presented as established causal facts merely from observational associations.

13. Cardiovascular Benefits: How Strong Is the Evidence?

The cardiovascular evidence is now one of the most important differentiators between GLP-1 therapies and older weight-loss medicines.

Outcome	Evidence status	Examples
Weight loss	Strong	STEP, SURMOUNT, OASIS, ATTAIN
Major cardiovascular events	Strong for selected populations	SELECT; cardiovascular outcome trials in diabetes
Kidney outcomes	Strong in specific populations	FLOW; supportive renal analyses
Heart failure outcomes	Strong and expanding	SUMMIT, STEP-HFpEF and related studies
MASH / liver disease	Promising to strong in studied histologic endpoints	ESSENCE
Cancer prevention	Not established	Research ongoing
Anti-aging	Not established as a primary indication	Biological and observational interest

An important distinction is that improvement in a risk factor is not equivalent to proof of reduction in clinical events. A lower blood pressure or triglyceride level may be beneficial, but an outcomes trial is needed to demonstrate that treatment actually reduces heart attacks, strokes, hospitalization or death.

14. GLP-1 Drugs and Cancer: What Do the Studies Actually Show?

GLP-1 medicines are increasingly discussed in relation to cancer because obesity, insulin resistance, inflammation and metabolic dysfunction are associated with several cancers.

However, the clinical evidence does not justify presenting semaglutide or tirzepatide as established anti-cancer drugs.

There is legitimate research interest in whether improving obesity, insulin resistance and metabolic health could eventually reduce the incidence or progression of particular cancers. But prevention, treatment and survival are separate questions, and randomized oncology trials would be required to establish a cancer-treatment indication.

Bottom line: Do not substitute GLP-1 therapy for standard cancer treatment. Any discussion of GLP-1 drugs in oncology should currently be framed as research or metabolic-risk context unless a specific indication is supported by clinical evidence and regulatory approval.

15. GLP-1 Drugs and the Brain

GLP-1 receptor agonists act partly through neural appetite-regulation pathways, which helps explain their effects on hunger, satiety and food intake.

Researchers are studying whether these pathways may also influence neuroinflammation, cognition, neurodegeneration or addictive behaviors.

These are scientifically interesting areas, but they should not be confused with established indications. Results from mechanistic, preclinical or early clinical studies are not equivalent to proof of treatment benefit.

16. What We Know — and What We Still Do Not Know

Question	Current evidence
Do GLP-1-based drugs cause substantial weight loss?	Yes. This is one of the strongest findings in the field.
Is tirzepatide more effective than semaglutide for average weight loss?	Yes in SURMOUNT-5, among adults with obesity without diabetes under the studied conditions.
Can semaglutide reduce cardiovascular events?	Yes in selected high-risk populations.
Can semaglutide improve kidney outcomes?	Yes in studied type 2 diabetes/chronic kidney disease populations.
Can tirzepatide improve obesity-related HFpEF outcomes?	Evidence supports benefit in the SUMMIT population.
Are oral GLP-1 drugs real clinical options?	Yes. Oral semaglutide and orforglipron have transformed the treatment landscape.
Is retatrutide approved?	No. It remains investigational.
Are GLP-1 drugs proven anti-cancer treatments?	No.
Are all GLP-1 drugs interchangeable?	No. Molecule, mechanism, dose, indication, evidence and safety profile differ.

17. OneDayMD Evidence Grading Framework

For readers trying to separate established medicine from speculation, a practical evidence hierarchy is useful.

Grade	Evidence type	Typical interpretation
E5	Large randomized controlled trial with clinically meaningful outcomes	High-confidence evidence for the population and endpoint studied
E4	Well-designed randomized trial, strong prospective evidence or consistent high-quality evidence	Strong evidence, but important limitations may remain
E3	Observational studies, secondary analyses, meta-analyses with important heterogeneity	Useful but vulnerable to confounding or indirectness
E2	Small clinical studies, exploratory analyses or uncontrolled cohorts	Hypothesis-generating
E1	Preclinical, laboratory or animal research	Mechanistic evidence, not proof of human benefit
E0	Testimonials, anecdotes, marketing claims or unsupported assertions	Not sufficient to establish efficacy

18. Clinical Takeaways

The GLP-1 field has entered a new phase. The question is no longer simply "Which drug causes the most weight loss?"

The more useful questions are:

Which mechanism?
Which indication?
Which patient population?
Which clinically meaningful endpoint?
What are the trade-offs?

Semaglutide has an unusually broad evidence base spanning obesity, cardiovascular disease and kidney outcomes. Tirzepatide has demonstrated greater average weight loss than semaglutide in a direct obesity trial and has produced important heart-failure findings. Oral semaglutide and orforglipron broaden the delivery options. Retatrutide is pushing the efficacy frontier even further, but it remains investigational.

The most important practical lesson is that weight loss alone is not enough to rank treatments. Long-term outcomes, tolerability, adherence, preservation of physical function, affordability, access and the patient's underlying diseases all matter.

OneDayMD perspective: GLP-1 therapy is best understood as part of a broader metabolic-health strategy. Medication can be powerful, but nutrition quality, adequate protein, resistance training, sleep, physical activity, cardiovascular risk management and long-term follow-up remain important components of care.

19. The 2026 GLP-1 Landscape at a Glance

Therapy	Mechanism	Major strength of evidence	2026 position
Semaglutide	GLP-1	Weight loss, cardiovascular and kidney outcomes; expanding liver data	Established
Tirzepatide	GIP + GLP-1	Very strong weight-loss evidence; cardiovascular and HFpEF evidence expanding	Established
Oral semaglutide	GLP-1	Weight loss and semaglutide outcome evidence base	Established
Orforglipron	Oral GLP-1	Phase 3 obesity data plus FDA approval	Established in U.S. obesity indication
Retatrutide	GIP + GLP-1 + glucagon	Very large phase 3 weight-loss results	Investigational
Zenagamtide / amycretin	GLP-1 + amylin	Promising phase 2 data; phase 3 development underway	Investigational

20. What Should Readers Watch Next?

The next generation of GLP-1 research is likely to focus less on proving that these drugs produce weight loss and more on what happens after the weight comes off.

Important areas include:

1. Long-term cardiovascular outcomes. Can benefits be sustained for many years?

2. Kidney protection across different populations. Which patients benefit most?

3. Heart failure. How broadly can incretin therapy be applied across HFpEF phenotypes?

4. Liver disease. Which incretin strategies provide the greatest benefit for fibrosis and long-term liver outcomes?

5. Muscle and physical function. How should treatment be paired with resistance training and nutrition?

6. Oral medicines. Will tablets significantly expand access and adherence?

7. Multi-receptor agonists. Will drugs such as retatrutide provide a clinically meaningful advantage over current therapies?

8. Personalized obesity medicine. Can patient characteristics, biomarkers or treatment response predict which incretin is best for an individual?

21. Key Studies and Authoritative Sources

Funding and conflicts: Many pivotal pharmaceutical trials are industry-funded. That does not invalidate their findings, but funding source should be considered when interpreting results. Large randomized trials, independent replication and real-world evidence remain important.

22. Frequently Asked Questions

What is the most important GLP-1 study?

There is no single best study for every question. SELECT is arguably one of the most important because it demonstrated cardiovascular risk reduction with semaglutide in adults with overweight or obesity and established cardiovascular disease without diabetes. STEP established major weight-loss efficacy, while FLOW expanded the evidence into kidney outcomes and SURMOUNT-5 directly compared tirzepatide with semaglutide.

Which causes more weight loss, semaglutide or tirzepatide?

In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide at 72 weeks: approximately 20.2% versus 13.7% in adults with obesity without diabetes.

Does semaglutide protect the heart?

Semaglutide has strong cardiovascular outcomes evidence. In SELECT, semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes.

Does semaglutide protect the kidneys?

Evidence from FLOW supports kidney benefits in people with type 2 diabetes and chronic kidney disease. The results should not automatically be generalized to every person taking semaglutide.

Is tirzepatide a GLP-1 drug?

Tirzepatide activates both the GIP and GLP-1 receptors. It is therefore often described as a dual incretin or dual GIP/GLP-1 receptor agonist rather than a conventional GLP-1-only drug.

Is retatrutide approved?

No. Retatrutide is an investigational triple agonist. Although phase 3 results reported very large weight reductions in 2025 and 2026, it remains distinct from FDA-approved semaglutide and tirzepatide products.

Is orforglipron approved?

Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026 for adults with obesity or adults with overweight and at least one weight-related comorbidity, together with reduced-calorie diet and increased physical activity.

Are oral GLP-1 drugs available?

Yes. Oral semaglutide products are now part of the U.S. Wegovy product family, and orforglipron was approved in 2026. This marks a major shift away from an exclusively injectable obesity-treatment market.

Can GLP-1 drugs treat cancer?

They are not established cancer treatments. Research into metabolic pathways, obesity-associated cancer risk and possible anticancer effects is ongoing, but GLP-1 medicines should not replace standard cancer therapy outside appropriate clinical research.

Do GLP-1 drugs cause muscle loss?

Weight loss can include a reduction in lean mass. The clinically important question is how much lean mass is lost relative to total weight reduction and whether strength and physical function are preserved. Adequate nutrition and resistance exercise are important components of a healthy weight-loss strategy.

Are GLP-1 drugs proven anti-aging medicines?

Not as a general anti-aging indication. They may improve several risk factors associated with healthier aging, but that is different from proving that a GLP-1 medicine slows biological aging or extends lifespan in healthy adults.

What is the future of GLP-1 therapy?

The field is moving toward oral medicines, higher-dose formulations, multi-receptor agonists and increasingly personalized treatment. Retatrutide and other next-generation agents may increase efficacy, but long-term cardiovascular, kidney, liver, muscle and safety data will be crucial.

Medical disclaimer: This page is for educational purposes only and does not provide individual medical advice, diagnosis or treatment. Prescription medicines should be used under the supervision of a qualified healthcare professional. Do not start, stop or change a prescription medication based solely on information on this website.

Related OneDayMD resources:

SELECT, STEP, SURPASS & FLOW GLP 1 Clinical Trials: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)
12 Best Natural Alternatives to Ozempic for Weight Loss (2026)

Where to Get Tirzepatide in 2026?

Oral Tirzepatide

Drop the pounds with needle-Free GLPs.
Low-dose, oral, dissolvable tablets to support your weight loss goals.
Supports fullness and reduced calorie intake
Needle-free alternative to injectable options
10 mg tablets compounded without artificial colors or dyes.

Where to buy Oral Tirzepatide Formula: Available on The Wellness Company's website. Here is the link: Tirzepatide.